Tarextumab

Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]

Tarextumab
Monoclonal antibody
Type?
SourceHuman
TargetNotch 2, Notch 3
Clinical data
Other namesOMP-59R5
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6338H9804N1700O1990S48
Molar mass143196.94 g·mol−1

See also

  • Notch signaling pathway, e.g. in embryo tissue development

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.